Cholinesterase inhibitors are the most effective treatment there is for the cognitive and neuropsychiatric symptoms of dementia with Lewy bodies. They are also withheld routinely, because bradycardia and conduction disease are common in these patients and the drug is cholinergic. This Lancet Neurology review argues the avoidance has outrun the evidence.
The cardiac abnormalities are part of the disease. Autonomic dysfunction and neurodegeneration produce bradycardia in dementia with Lewy bodies independently of any drug, which means a slow pulse at baseline is expected rather than a warning. Randomised trial and meta-analysis evidence, the authors set out, supports a favourable cardiac safety profile for cholinesterase inhibitors in this population, including in patients who already have conduction abnormalities, without an increase in major cardiovascular events.
This is a review rather than a new trial, so it is a synthesis of what already exists plus expert judgement, and it does not remove the need for care in a patient with high-grade block or a very slow resting rate. What it does is shift the default. The question is no longer whether the patient's ECG permits treatment, but what monitoring lets treatment go ahead.
So in practice: get a baseline ECG and pulse, start at a low dose, review at four to six weeks with the rate rechecked, and involve cardiology rather than the drug chart when the ECG is genuinely abnormal. A patient with distressing visual hallucinations and fluctuating cognition who has never had a cholinesterase inhibitor because of a first-degree block is the patient this review is about.
- Record baseline resting pulse and a 12-lead ECG before starting - as a comparator, not as a gate
- Expect bradycardia in dementia with Lewy bodies; it is part of the disease, not necessarily the drug
- Recheck the pulse at four to six weeks and again after any dose increase
- Ask cardiology about high-grade block or symptomatic bradycardia rather than simply not prescribing
- Review the drug chart for other rate-slowing agents - beta blockers and donepezil together are the real risk
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for neurology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free